Expression of hepatitis B virus surface antigen gene in Escherichia coli

Pumpen, P.; Kozlovskaya, T.; Borisova, Galina; Bichko, V.; Dishler, A. V.; Kalis, Janal M.; Kukaine, R. A.; Gren, E.J.

doi:10.1016/0378-1119(84)90121-5

Cited by 14 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first reports on the cloning of the full HBV genome date back to the late nineteen-seventies to early nineteen-eighties [ 5 , 6 , 7 , 8 ]. With the cloning of the HBV genome and the identification of the HBV S gene (HBs) in 1979, a new era of HBs-based vaccine design and production was entered.…”

Section: Introductionmentioning

confidence: 99%

Production of the HBc Protein from Different HBV Genotypes in E. coli. Use of Reassociated HBc VLPs for Packaging of ss- and dsRNA

et al. 2021

View full text Add to dashboard Cite

The core proteins (HBc) of the hepatitis B virus (HBV) genotypes A, B, C, D, E, F, and G were cloned and expressed in Escherichia coli (E. coli), and HBc-formed virus-like particles (VLPs) were purified with ammonium sulfate precipitation, gel filtration, and ion exchange chromatography (IEX). The best VLP yield was found for the HBc of the HBV genotypes D and G. For the HBc of the HBV genotypes D, F, and G, the possibility of dissociation and reassociation maintaining the native HBc structure was demonstrated. Single-stranded (ss) and double-stranded (ds) ribonucleic acid (RNA) was successfully packed into HBc VLPs for the HBV genotypes D and G.

show abstract

Section: Introductionmentioning

confidence: 99%

Production of the HBc Protein from Different HBV Genotypes in E. coli. Use of Reassociated HBc VLPs for Packaging of ss- and dsRNA

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For monitoring of the humoral response, immune serum was collected 14 days after the first and second immunizations. For T-cell proliferation tests, mice were sacrificed and spleens were obtained at day 28 ELISAs. Direct and competitive enzyme-linked immunosorbent assays (ELISAs) were performed, in general, as described in reference 36.…”

Section: Constructionmentioning

confidence: 99%

Construction and Immunological Evaluation of Multivalent Hepatitis B Virus (HBV) Core Virus-Like Particles Carrying HBV and HCV Epitopes

Sominskaya

Skrastiņa

Dislers

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

A multivalent vaccine candidate against hepatitis B virus (HBV) and hepatitis C virus (HCV) infections was constructed on the basis of HBV core (HBc) virus-like particles (VLPs) as carriers. Chimeric VLPs that carried a virus-neutralizing HBV pre-S1 epitope corresponding to amino acids (aa) 20 to 47 in the major immunodominant region (MIR) and a highly conserved N-terminal HCV core epitope corresponding to aa 1 to 60 at the C terminus of the truncated HBc⌬ protein (N-terminal aa 1 to 144 of full-length HBc) were produced in Escherichia coli cells and examined for their antigenicity and immunogenicity. The presence of two different foreign epitopes within the HBc molecule did not interfere with its VLP-forming ability, with the HBV pre-S1 epitope exposed on the surface and the HCV core epitope buried within the VLPs. After immunization of BALB/c mice, specific T-cell activation by both foreign epitopes and a high-titer antibody response against the pre-S1 epitope were found, whereas an antibody response against the HBc carrier was notably suppressed. Both inserted epitopes also induced a specific cytotoxic-T-lymphocyte (CTL) response, as shown by the gamma interferon (IFN-␥) production profile.Genetically engineered virus-like particle (VLP)-based vaccines are one of the most promising tools in modern vaccinology. VLPs from almost all classes of viruses are being evaluated now or have just been adopted to use as carriers for presentation of foreign immunological epitopes (for a review, see references 29 and 31). VLP technologies possess obvious advantages for the generation of safe and efficacious vaccines. First, the repetitive antigenic structure of VLPs makes them highly immunogenic. Second, VLPs lack viral genomes or genes and are noninfectious, although they mimic infectious viruses in their structural and immunological features. Third, VLPs are generated by highly efficient heterologous expression of the cloned viral structural genes with subsequent quantitative in vivo or in vitro self-assembly of their products. Fourth, VLPs can be obtained by simple and efficient purification procedures. VLPs can be used for a broad range of applications, but the generation of vaccines against hepatitis B virus (HBV) and hepatitis C virus (HCV) infections is of special interest.The HBV core (HBc) protein was first reported as a promising VLP carrier in 1986 and was published in 1987 (6, 10, 24). In many ways, HBc occupies a unique position among the VLP carriers because of its high-level synthesis and efficient selfassembly in virtually all known homologous and heterologous expression systems, including bacteria (for a review, see references 29 to 31). The major HBc B-cell epitopes (c and e1) are localized within the major immunodominant region (MIR), whereas the next important epitope, e2, is localized around amino acid position 130, close to the C-terminal histone-like region (for a review, see reference 30).The high-resolution spatial structure of HBc icosahedrons (11,43) shows that the MIR is located on the tip of th...

show abstract

“…In previous papers we described appearance of HBV genotypes in Latvia [10,11] and their distribution in two Latvian clinics: the Kidney transplantation Centre and the Hematology Unit of the Children's Clinical University Hospital in Riga [12,13]. Due to the specific nature of the clinics obtained data represented exclusively the HBV genome distribution for different sorts of chronic HBV infection.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B Virus Genotypes in Latvia

Sominskaya¹

2011

TOHEPATJ

View full text Add to dashboard Cite

Abstract:The aim of this study was to investigate the properties of HBV genomes isolated from patients with acute and chronic hepatitis, liver cirrhosis, and hepatic coma admitted to the Infectology Center of Latvia. HBV genotypes and HBsAg subtypes were determined by direct S-gene sequencing. Genotypes D (72.17%) and A (27.96%) were predominant. Only one case (0.87%) of HBV genotype E was found. Prevalence of genotype D over genotype A was more strongly pronounced in isolates from patients with acute hepatitis than from patients with chronic hepatitis-74%-24% and 68%-32%, respectively. Number of previously described and some new mutations (Ser21Thr in preC region, Tyr134Lys, Phe134Leu, Ile110Met, Thr118Ile and Ser136Tyr in S-gene) were discovered by direct sequencing of PCR fragments corresponding to preS/S and preC/C regions and to a fragment of the X gene of HBV genome. The most frequently mutations were found in the region of the basal core promoter, preC and major immunodominant region of core protein and domain a of S protein. In general the rate of mutations discovered in chronic patients was just 1,23 times higher then in patients with acute hepatitis, at the same time the ratio for the hot-spot preC 1896 stop mutation was higher and reached 1,81. A possible role of discovered mutations in the HBV pathogenesis is discussed. The findings are relevant to diagnosis and prognosis of HBV-induced liver disease.

show abstract

Expression of hepatitis B virus surface antigen gene in Escherichia coli

Cited by 14 publications

References 29 publications

Production of the HBc Protein from Different HBV Genotypes in E. coli. Use of Reassociated HBc VLPs for Packaging of ss- and dsRNA

Production of the HBc Protein from Different HBV Genotypes in E. coli. Use of Reassociated HBc VLPs for Packaging of ss- and dsRNA

Construction and Immunological Evaluation of Multivalent Hepatitis B Virus (HBV) Core Virus-Like Particles Carrying HBV and HCV Epitopes

Hepatitis B Virus Genotypes in Latvia

Contact Info

Product

Resources

About